Previous close | 77.81 |
Open | 77.78 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 77.65 - 78.93 |
52-week range | 57.17 - 89.74 |
Volume | |
Avg. volume | 6,194,930 |
Market cap | 98.222B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 21.82 |
EPS (TTM) | 3.61 |
Earnings date | 26 Apr 2023 - 01 May 2023 |
Forward dividend & yield | 3.00 (3.78%) |
Ex-dividend date | 14 Mar 2023 |
1y target est | 88.96 |
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.